GSK PLC
[WKN: A3DMB5 | ISIN: GB00BN7SWP63]
Aktienkurse
17,418€ -0,85%
Echtzeit-Aktienkurs GSK PLC
Bid: Ask:
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

GSK sees positive COPD trial results

GSK PLC (LSE:GSK, NYSE:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive...…

GSK wins Illinois Zantac court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK wins Illinois court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK: Impfstoffsegment enttäuscht - Aktienanalyse

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

GSK 100% backs London listing, says boss

GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent…

GSK appeals Delaware Zantac ruling

GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting…

GSK found not guilty in Zantac trial

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois,…

GSK found not guilty in Zantac trial

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois,…